SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?


To: MoneyMade who wrote (951)3/25/1999 4:24:00 PM
From: Speedster  Read Replies (2) | Respond to of 1837
 
cnbc.com



To: MoneyMade who wrote (951)3/25/1999 5:03:00 PM
From: Instock  Read Replies (3) | Respond to of 1837
 
The conference call (1-888-266-2081. Password: 1419338, for replay) said they had a letter of intent signed with a Fortune
200 company, for marketing of Cenestin - and that the agreement would be finalized in a few days. Looking at the Fortune
500 list, I see 4 pharmaceutical firms in the Fortune 200 list: Eli Lily, Warner-Lambert, Abbott and Pfizer. I wonder which
firm it is.

Conference call also said Premarin has 70% of the estrogen market; that market is currently $2 billion a year and growing at
15% annually.

RePost from Yahoo:
marketing agreement
by: nicegirl99 (F/Planet Earth)
5686 of 5686